{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-099383","form_type":"8-K","ticker":"EYPT","cik":"0001314102","company_name":"EyePoint, Inc.","filed_at":"2025-07-29T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.631818+00:00","generated_at":"2026-05-17T23:33:46.629676+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"EyePoint finishes Phase 3 enrollment for DURAVYU in wet AMD; top-line data mid-2026","bullets":["LUCIA trial enrolled and randomized over 400 patients in seven months; total >800 across both trials.","Interim safety data consistent with prior DURAVYU trials; DSMC recommended continuation without protocol changes.","Topline 56-week data for LUGANO expected mid-2026; LUCIA data to follow shortly after.","DURAVYU is a sustained-release TKI for wet AMD; Phase 3 program aligned with FDA and EMA.","DURAVYU has been evaluated in over 190 patients across four trials with favorable safety profile."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-099383","json":"https://secwatch.observer/filing/0000950170-25-099383.json","markdown":"https://secwatch.observer/filing/0000950170-25-099383.md","text":"https://secwatch.observer/filing/0000950170-25-099383.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1314102/000095017025099383/0000950170-25-099383-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1314102/000095017025099383/eypt-20250729.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T23:33:46.629676+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}